ArticlePloS one2025
Bioinformatics analysis to explore biomarkers and mechanisms of action associated with endoplasmic reticulum stress and ferroptosis in Parkinson's disease.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt has been demonstrated that Parkinson's disease (PD) is closely associated with endoplasmic reticulum stress (ERS) and ferroptosis. However, the specific mechanisms underlying these associations remain unclear. Consequently, this study investigated the mechanisms connecting these factors and explored potential biomarkers for PD.
methodsData for PD and ERS, as well as information on ferroptosis, were sourced from public databases and relevant literature. Candidate genes were identified through differential expression analysis and weighted gene co-expression network analysis. Further investigations included functional enrichment analysis, the construction of a protein-protein interaction (PPI) network, and the examination of related genes. Subsequently, biomarkers were validated using the least absolute shrinkage and selection operator regression algorithm. Additionally, correlations among biomarkers, gene set enrichment analysis, chromosomal and subcellular localization, immune cell infiltration, regulatory mechanisms, and drug predictions were conducted.
resultsInitially, seven candidate genes were identified, predominantly associated with type II diabetes mellitus. Furthermore, five interacting associations within the PPI network and twenty related genes were identified, primarily engaged in the physical interactions pathway. Subsequently, three biomarkers were screened: N-myc downstream-regulated gene 1 (NDRG1), dihydrolipoamide dehydrogenase (DLD), and cold-inducible RNA-binding protein (CIRBP). A detailed analysis revealed a positive correlation between CIRBP and DLD, while NDRG1 exhibited a negative correlation with DLD; all three biomarkers were chiefly enriched in the oxidative phosphorylation pathway and PD. NDRG1 is located on chromosome 8, DLD on chromosome 7, and CIRBP on chromosome 19, with all three primarily localized in the nucleus. A total of 31 differential immune cells were identified between the disease and control groups, with neurons representing the highest proportion and the most significant negative correlation observed between DLD and pro B-cells. The interactions involving NORAD-hsa-miR-1277-5p-DLD, NEAT1-hsa-miR-128-3p-CIRBP, and XIST-hsa-miR-3173-5p-NDRG1 were found to be pivotal. Additionally, these biomarkers were regulated by 15 common transcription factors. Finally, nicotinamide adenine dinucleotide, pyruvic acid, nitric oxide, and phosphates were predicted as potential co-targeted therapeutic agents.
conclusionsNDRG1, DLD, and CIRBP were identified as biomarkers for PD, thereby opening new avenues for elucidating disease mechanisms, facilitating early diagnosis, and identifying potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.